iShares Biotechnology ETF $IBB Stock Holdings Increased by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lifted its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 16.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 147,707 shares of the financial services provider’s stock after acquiring an additional 21,052 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in iShares Biotechnology ETF were worth $24,929,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in IBB. Citigroup Inc. boosted its position in iShares Biotechnology ETF by 40.9% during the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after acquiring an additional 1,521,992 shares during the period. Morgan Stanley increased its holdings in shares of iShares Biotechnology ETF by 2.5% during the fourth quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock valued at $540,760,000 after purchasing an additional 76,978 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of iShares Biotechnology ETF by 11.4% during the fourth quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after purchasing an additional 218,066 shares during the period. Raymond James Financial Inc. increased its holdings in shares of iShares Biotechnology ETF by 286.2% during the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after purchasing an additional 736,881 shares during the period. Finally, LPL Financial LLC raised its stake in shares of iShares Biotechnology ETF by 145.9% during the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after purchasing an additional 589,033 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Stock Performance

IBB stock opened at $177.00 on Tuesday. The firm’s 50-day moving average is $170.71 and its two-hundred day moving average is $170.72. iShares Biotechnology ETF has a 52 week low of $123.61 and a 52 week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were issued a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date was Monday, June 15th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.